fda warning letter glp-1 october 2025 issued 30 letters to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading FDA Sends Warning Letters to

GLP-1 receptor agonists now join this group as a class of agents with broad and expanding clinical implications

SEMA: semaglutida subcutnea semanal 2,4mg

Generating 495 billion reais and surpassing the 455 billion from the previous year, the bar and restaurant sector in Brazil grew in 2025, with an increase that, when adjusted for inflation, was much more modest, at less than 1% in the country

Amylopectin branch chains are further divided into types A, B and C

Disulfide-bond-induced structural frustration and dynamic disorder in a peroxiredoxin from MAS NMR

It can have a major impact on the life of a young person, as well as those around them